Organon Discussing Status Of Pending NDAs With FDA After Warning Letter
Executive Summary
Organon is discussing the status of two pending applications with FDA after receiving a warning letter from the agency
You may also be interested in...
Organon Building New Quality Affairs Group; New Jersey Plant To Close
Organon plans to build a new quality affairs organization with a staff of 45-50 employees following the closure of its injectable drug manufacturing facility in West Orange, N.J
Organon Building New Quality Affairs Group; New Jersey Plant To Close
Organon plans to build a new quality affairs organization with a staff of 45-50 employees following the closure of its injectable drug manufacturing facility in West Orange, N.J
Pfizer/Organon Antipsychotic Deal: Positive Thoughts On Negative Symptoms
Pfizer is paying $100 mil. up front for a second chance at the antipsychotic market through a licensing deal with Akzo Nobel's pharmaceutical division Organon